[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
|
[2]TONG MJ, ROSINSKI AA, HUYNH CT, et al.Long-term survival after surveillance and reatment in patients with chronic viral hepatitis and hepatocellular carcinoma[J].Hepatol Commun, 2017, 1 (7) :595-608.
|
[3]National Health and Family Planning Commission of the People’s Republic of China.Diagnosis, management and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
|
[4]ZHANG CY, FU Y, LI XD, et al.Advances in imaging diagnosis of liver cancer[J].J Clin Hepatol, 2017, 33 (7) :1266-1269. (in Chinese) 张春雨, 付宇, 李晓东, 等.肝癌的影像学诊断进展[J].临床肝胆病杂志, 2017, 33 (7) :1266-1269.
|
[5]ZHONG JH, PENG NF, YOU XM, et al.Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China:A real-world study[J].Oncotarget, 2017, 8 (11) :18296-18302.
|
[6]PANDYA P, KANWAL F.Adding to the evidence base:Effectiveness of hepatocellular carcinoma surveillance in clinical practice[J].Hepatol Commun, 2017, 1 (8) :723-725.
|
[7]JEONG WK.Surveillance of hepatocellular carcinoma:Is only ultrasound enough?[J].Clin Mol Hepatol, 2017, 23 (3) :222-223.
|
[8]TZARTZEVA K, OBI J, RICH NE, et al.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis:A Meta-analysis[J].Gastroenterology, 2018, 154 (6) :1706-1718.
|
[9]FREY RS, BOLDANOVA T, HEIM M.Ultrasound surveillance for hepatocellular carcinoma:Real-life performance in a hepatology outpatient clinic[J].Swiss Med Wkly, 2015, 145:w14200.
|
[10]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.
|
[11]WANG M, DEVARAJAN K, SINGAL AG, et al.The Doylestown algorithm:A test to improve the performance of AFP in the detection of hepatocellular carcinoma[J].Cancer Prev Res, 2016, 9 (2) :172-179.
|
[12]SONG PP, XIA JF, INAGAKI Y, et al.Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22 (1) :262-274.
|
[13]WONG RJ, AHMED A, GISH RG.Elevated alpha-fetoprotein:Differential diagnosis-hepatocellular carcinoma and other disorders[J].Clin Liver Dis, 2015, 19 (2) :309-323.
|
[14]AHMED MOHAMMED HF, ROBERTS LR.Should AFP (or any biomarkers) be used for HCC surveillance?[J].Curr Hepatol Rep, 2017, 16 (2) :137-145.
|
[15]OMATA M, CHENG AL, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J].Hepatol Int, 2017, 11 (4) :317-370.
|
[16]LI B, LI B, GUO T, et al.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels ofα-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73[J].Oncotarget, 2017, 8 (46) :80521-80530.
|
[17]YANG GM, ZHAO YS, WANG CH, et al.Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (1) :199-203. (in Chinese) 杨贵敏, 赵运盛, 王春华, 等.肝细胞癌肿瘤标志物的研究进展[J].临床肝胆病杂志, 2018, 34 (1) :199-203.
|
[18]WANG J, ZHANG SG, SUN Y, et al.The application value of GPC-3 and CK-19 in the diagnosis of hepatocellular carcinoma[J].J Clin Exp Med, 2017, 16 (14) :1398-1404. (in Chinese) 王娟, 张曙光, 孙颖, 等.免疫组化检测GPC-3与CK-19在肝细胞癌诊断中的应用价值[J].临床和实验医学杂志, 2017, 16 (14) :1398-1404.
|
[19]SU YH, LIN SY, SONG W, et al.DNA markers in molecular diagnostics for hepatocellular carcinoma[J].Expert Rev Mol Diagn, 2014, 14 (7) :803-817.
|
[20]XU RH, WEI W, KRAWCZYK M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J].Nat Mater, 2017, 16 (11) :1155-1161.
|
[21]DUCHARTRE Y, KIM YM, KAHN M.The Wnt signaling pathway in cancer[J].Crit Rev Oncol Hematol, 2016, 99:141-149.
|
[22]BAI ZF, DONG F, CHAI X, et al.Research advances on the serological markers in early screening and diagnosis of hepatocellular carcinoma[J].Chin J Gastroenter Hepatol, 2016, 25 (5) :589-593. (in Chinese) 柏兆方, 董方, 柴煊, 等.肝癌血清学早期筛查与诊断标志物研究进展[J].胃肠病学和肝病学杂志, 2016, 25 (5) :589-593.
|
[23]ZHANG Z, ZHANG Y, WANG Y, et al.Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J].Onco Targets and therapy, 2016, 9:123-129.
|
[24]JIA Z, WANG L, LIU C, et al.Evaluation ofα-fetoprotein-L3and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma[J].Contemp Oncol, 2014, 18 (3) :192-196.
|
[25]JUNNA Z, GONGDE C, JINYING X, et al.Serum AFU, 5'-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis[J].Open Med, 2017, 12 (1) :354-358.
|
[26]LI C, ZHANG Z, ZHANG P, et al.Diagnostic accuracy of desgamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma:A systematic review[J].Hepatol Res, 2014, 44:e11-e25.
|
[27]PARK SJ, JANG JY, JEONG SW, et al.Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma[J].Medicine (Baltimore) , 2017, 96 (11) :e5811.
|
[28]ZHANG XM, WEI MJ, XU ZJ, et al.Pattern of serumα-fetal protein, intereleukin-6 and Golgi protein 73 expressed in liver disease and their diagnostic value on hepatocellular carcinoma[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (4) :339-344. (in Chinese) 张小曼, 魏梅娟, 许正锯, 等.血清甲胎蛋白、白细胞介素-6和高尔基体蛋白73在肝脏疾病中的表达特点及其对肝细胞癌的诊断价值[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (4) :339-344.
|
[29]ZHU J, JIANG F, NI HB, et al.Combined analysis of serumγ-glutamyl transferase isoenzyme II, α-L-fucosidase andα-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma[J].Exp Ther Med, 2013, 5 (1) :89-94.
|
[30]CHEN H, CHEN S, LI S, et al.Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing:An update meta-analysis and validation study[J].Oncotarget, 2017, 8 (52) :90390-90401.
|
[31]MITTAL S, KANWAL F, YING J, et al.Effectiveness of surveillance for hepatocellular carcinoma in clinical practice:A United States cohort[J].J Hepatol, 2016, 65 (6) :1148-1154.
|
[32]GOLDBERG DS, ADDEI TH, SERPER M, et al.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis[J].Hepatology, 2017, 65 (3) :864-874.
|
[33]DING HG.Standardized screening and monitoring of primary liver cancer should be taken seriously[J].Beijing Med J, 2013, 35 (6) :409-411. (in Chinese) 丁惠国.重视原发性肝癌的规范化筛查与监测[J].北京医学, 2013, 35 (6) :409-411.
|
[34]HAN KH, AHN SH.How to predict HCC development in patients with chronic B viral liver disease[J].Intervirology, 2005, 48 (1) :23-28.
|
[35]YANG HI, SHERMAN M, SU J, et al.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J].J Clin Oncol, 2010, 28 (14) :2437-2444.
|
[36]KIM WR, LOOMBA R, BERG T, et al.Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J].Cancer, 2015, 121 (20) :3631-3638.
|
[37]PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J].J Hepatol, 2016, 64 (4) :800-806.
|
[38]HUNG YC, LIIN CL, LIU CJ, et al.Development of risk scoring system for stratifying population for hepatocellular carcinoma screening[J].Hepatology, 2015, 61 (6) :1934-1944.
|
[39]FLEMMING JA, YANG JD, VITTINGHOFF E, et al.Risk prediction of hepatocellular carcinoma in patients with circhosis:The ADRESS-HCC risk model[J].Cancer, 2014, 120 (22) :3485-3493.
|
[40]WATANABE M, YOMOKORI H, TAKAHASHI Y, et al.Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis:A single regional community hospital study[J].Turk J Gastroenterol, 2017, 28 (5) :353-360.
|
[41]ATIQ O, TIRO J, YOPP AC, et al.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis[J].Hepatology, 2017, 65 (4) :1196-1205.
|
[42]LI P, DING HG, XU H, et al.Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1301-1304. (in Chinese) 李鹏, 丁惠国, 徐辉, 等.缩短肝癌筛查间隔对乙型肝炎肝硬化相关肝细胞癌患者预后的影响[J].临床肝胆病杂志, 2017, 33 (7) :1301-1304.
|